Skip to content

For full details on each session, please view the event guide.

7:30 am Welcome Coffee & Registration

8:20 am Chair’s Opening Remarks

Utilise the Advantages of Specific Model Type to Your Research Objectives

8:30 am Preclinical Modelling of Immuno-Oncology Therapies

9:00 am Patient-Derived Experimental Models for Translational Cancer Research

  • Ludovic Bourré Senior Director, Scientific Engagement , Crown Bioscience

9:30 am Unique PDX Models to Advance Liquid-Biopsy Research & Immunotherapy

  • Neta Moskovits Head of The Translational Cancer Research lab, Rabin Medical Center

10:00 am Sophisticated Humanised Mouse Models to Investigate the Mechanisms of Immunotherapy

  • Ralph Gareus Director Business Development Europe, The Jackson Laboratory

10:30 am Speed Networking

11:15 am Morning Refreshments

11:45 am Assessment of Different Humanised Mouse Models for the Evaluation of Cancer Immunotherapies

12:15 pm Panel Discussion – Industry Insight: How to Utilise Complimentary Models to Drive Drug Discovery Development

  • Sukhvinder Sidhu Global Head of Pharmacology, Sanofi
  • Anita Seshire Head of Laboratory Cellular Pharmacology & Translational Innovation Platform Oncology, Merck Healthcare KGaA
  • Paul McSheehy Senior Scientist & Leader - Cancer Biology In Vivo & Translational Science Oncology, Basilea Pharmaceutica
  • Ralph Gareus Director Business Development Europe, The Jackson Laboratory
  • Ludovic Bourré Senior Director, Scientific Engagement , Crown Bioscience

1:00 pm Lunch and Networking

Apply Complex 3D Models to Support In Vivo Modelling Outcomes

2:00 pm 3D Cancer Stem Cell Models to Study Microenvironment Interactions and Tumour Plasticity

  • Anita Seshire Head of Laboratory Cellular Pharmacology & Translational Innovation Platform Oncology, Merck Healthcare KGaA

2:30 pm Early In Vivo Identification of Low Value Molecules

3:00 pm Re-Balancing the Suppressive Tumour Environment – Restoring an Effective Immune Response

3:30 pm Syngeneic Models of Breast Cancer: Effects of Immune Modulatory Agents in Classically “Cold” Tumours

3:45 pm Afternoon Break & Networking

4:15 pm Preclinical Profiling of Derazantinib (BAL087), an FGF-R Inhibitor Currently in Phase-2 Clinical Trials

  • Paul McSheehy Senior Scientist & Leader - Cancer Biology In Vivo & Translational Science Oncology, Basilea Pharmaceutica

4:45 pm SRG OncoRat – An Immunodeficient Rat Model to Compliment your Oncology Program

5:00 pm Chair’s Closing Remarks

5:15 pm Evening Drinks Reception & Poster Reception

For full details on each session, please view the event guide.